{"name":"Civi Biopharma, Inc.","slug":"civi-biopharma-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CIVI 007","genericName":"CIVI 007","slug":"civi-007","indication":"Other","status":"phase_2"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Iloprost Injection, for intravenous use","genericName":"Iloprost Injection, for intravenous use","slug":"iloprost-injection-for-intravenous-use","indication":"Pulmonary arterial hypertension","status":"phase_3"}]}],"pipeline":[{"name":"CIVI 007","genericName":"CIVI 007","slug":"civi-007","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Iloprost Injection, for intravenous use","genericName":"Iloprost Injection, for intravenous use","slug":"iloprost-injection-for-intravenous-use","phase":"phase_3","mechanism":"Iloprost is a prostacyclin analog that binds to prostacyclin receptors on vascular endothelial and smooth muscle cells, promoting vasodilation and inhibiting platelet aggregation.","indications":["Pulmonary arterial hypertension","Raynaud's phenomenon secondary to systemic sclerosis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxQWUV0WUhKYUJuek5Qa19selJLZ19CTGlRN0N1VWhnWU05WFBidi1PYWVrSEJiOUpxclE4enpZSDY4UktQaDZSZUdvX1B5UFdHVG4wSndVbl9UMU1vTU9ZLVJZU0NTZTFkSFJFZDU4ZkVTMlNoM0pqTkVHa2xLYjNScW13My11Yk5yRXktaTdsRThzQnR3bjZ4RUY4dlhOUnpEM2lYbXJwVWhaR0dLelNPTzhKMHIyUVlVWTRuTkhXeENrMWFWV25CTDQxcVZ0MmpfaHRJZDlpenlNelZMYjFWb2VJMTlVZ1JfTUh6MlJpX0tkaEZyYzJhN2tYdXU?oc=5","date":"2025-05-08","type":"pipeline","source":"PR Newswire","summary":"LEQVIO Strengthens Position as Leader in Cholesterol-Lowering Therapies Across Seven Major Markets | DelveInsight - PR Newswire","headline":"LEQVIO Strengthens Position as Leader in Cholesterol-Lowering Therapies Across Seven Major Markets | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAJBVV95cUxOaVl3aXFiU3F2cWR0NlRkM0Ixb1RtR3Z4d1h0ZDlVRjFOUUhfeENIWGdvbHV1cllCS3NsdmRmT202Sk16VXVEbGRFQUp6ZlNRY1B3XzBCV2ZlTmRxS2NJNVl4Zno3ZlhzejRMaTFOWnQ3QWZWUnFpUXl6UEJyWkFLSXFHX2VwNmltdFlXNnozRmVIdmpBdERnUVNmblQ5WElxVGZvUmNtUUZmRzhoOFJqaGxsVFhKTkQzX0FoeDJ3Y2NJSENMTzNXaGxSejdYSlR2RzNmaGZyWkpnaWlOWXVQZ3k4NjAwR3Q5MlRpLWZubDk4OG9OTkhoTXY5S3hJUTRpc0lrLVlBRWxLUjl0OXNPOUtqVUsxVWt2ZUhPeU8zdEthY213SmdodEl2a1ZfNVB2R20zU1Z3VE5vcHhndjh3aDZkUEMxTU5w?oc=5","date":"2025-04-16","type":"regulatory","source":"PR Newswire","summary":"ANGPTL3 Inhibitor Market Set for Robust Growth During the Forecast Period (2025-2034) Across 7MM Owing to the Rising Demand for Novel Lipid-Lowering Therapies | DelveInsight - PR Newswire","headline":"ANGPTL3 Inhibitor Market Set for Robust Growth During the Forecast Period (2025-2034) Across 7MM Owing to the Rising Dem","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgJBVV95cUxPRkF5bkpUT0NLYWlJTUpBcHRRLTdrOWhMYkp6UGFrOWJndV9UN2N1MDFsck1lblJYNW5MZ1ZmVDItNkZqVjl6S0x0RVhXbVhOVHY4SmUwdFlXV1c5RWxWM0JjbXIwbWw0bFR2anJJeXJCTHhidWNJcjFZZFpoeXpkUGdkQ2c1Q2VWNGxqNWZUVWExSGFHS3JWUjMxSjl1OTNsS1dVdU51bTl5Y3k0aG16UFkwcWQ1V1U4REQwekpBaG9GRDFudzY1SHo1cG5CaVN1amlvVWs3eGV4TE9zaGVUU3dqanV2Uk5yTk5Ic3dOT2FTRnBMLXcwR1BiZTF3azlpWjhCczZaaTBiLVYwVUJBNjkxT0tKaVA3czhUeUpZZGQwNmk4QzZIYUZGTW4tS1pMLTFBSEZ2UU5kbFNleVQzQTMxa3pHWXVqWFBHakNn?oc=5","date":"2025-02-17","type":"pipeline","source":"GlobeNewswire","summary":"PCSK9 Inhibitors Market Anticipate to Accelerate in the - GlobeNewswire","headline":"PCSK9 Inhibitors Market Anticipate to Accelerate in the","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE1lQzBHZllROXdvNktCRUhuRURvM3pTdnAyN1hNb1RTR3Q4WlR6SERBcHJDX3NfQWlRT2ZwbDlMX2ljX19ReTZERWlaZU04Wllxb0ZCTVdEbXNhX1FyaWZwbjQ1SQ?oc=5","date":"2023-09-18","type":"trial","source":"Wiley Online Library","summary":"Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis - Wiley Online Library","headline":"Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed no","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxQOE5FeU1CbWJjM09fTWxQVWJEbUtZWE9sUlJJU19hSnM3Mm8tOG5qUmFkcWFMa0VjVUZIRmZncTNrTXNpYjRNd0J2cnBfQW1VMTZ6cTFRaVVqUGZGZTdFMGV3cXd1TjFiX3VYWGFrM2JCbVNhUnpOYUFoeEw3cGpfYno4Z1JiQ3I0LWpEQUVxYVRKTXptMGpHR1JCRktBcE52ZGV6bTM5TE4wVkFRZ1Y3ZW5yZTU4M2FoS2RpN296ZlRYRmN3TDZwTXV5bXlvTnhCanJ5WG1BcG1razhXcnF4cXZNdmxfR2s?oc=5","date":"2017-01-05","type":"pipeline","source":"PR Newswire","summary":"CiVi Biopharma Raises $40 Million in Series A Financing From Boxer Capital of the Tavistock Group - PR Newswire","headline":"CiVi Biopharma Raises $40 Million in Series A Financing From Boxer Capital of the Tavistock Group","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}